{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:00:19Z","timestamp":1789974019955,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"DOI":"10.1007\/s11845-026-04646-y","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:05:37Z","timestamp":1789970737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in statin therapy following discharge in those with cardiovascular disease in Ireland"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7055-4530","authenticated-orcid":false,"given":"Cillian","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor J","family":"McCaughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"1","key":"4646_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/eurheartj\/ehz859","volume":"41","author":"A Timmis","year":"2020","unstructured":"Timmis A et al (2020) European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J 41(1):12\u201385","journal-title":"Eur Heart J"},{"issue":"25","key":"4646_CR2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA et al (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study. J Am Coll Cardiol 76(25):2982\u20133021","journal-title":"J Am Coll Cardiol"},{"key":"4646_CR3","unstructured":"Office CS (2023) Vital statistics yearly summary. [Accessed 01\/01\/2024]; Available from: https:\/\/www.cso.ie\/en\/releasesandpublications\/ep\/p-vsys\/vitalstatisticsyearlysummary2023\/"},{"key":"4646_CR4","unstructured":"World Health Organization Cardiovascular disease: avoiding heart attacks and strokes. [Accessed 07\/01\/2024]; Available from: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/cardiovascular-diseases-avoiding-heart-attacks-and-strokes"},{"issue":"9438","key":"4646_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937\u2013952","journal-title":"Lancet"},{"issue":"1","key":"4646_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.110.957944","volume":"4","author":"TG Briffa","year":"2011","unstructured":"Briffa TG et al (2011) Population trends of recurrent coronary heart disease event rates remain high. Circ Cardiovasc Qual Outcomes 4(1):107\u2013113","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"34","key":"4646_CR7","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ et al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227\u20133337","journal-title":"Eur Heart J"},{"issue":"24","key":"4646_CR8","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM et al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(24):3168\u20133209","journal-title":"J Am Coll Cardiol"},{"issue":"9753","key":"4646_CR9","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670\u20131681","journal-title":"Lancet"},{"key":"4646_CR10","doi-asserted-by":"crossref","unstructured":"Pedersen TR et al (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383\u20131389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"issue":"7","key":"4646_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H et al (2013) Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 158(7):526\u2013534","journal-title":"Ann Intern Med"},{"issue":"1","key":"4646_CR12","doi-asserted-by":"publisher","first-page":"e001659","DOI":"10.1136\/openhrt-2021-001659","volume":"8","author":"JM Curneen","year":"2021","unstructured":"Curneen JM et al (2021) Interhospital and interindividual variability in secondary prevention: a comparison of outpatients with a history of chronic coronary syndrome versus outpatients with a history of acute coronary syndrome (the iASPIRE Study). Open Heart 8(1):e001659. https:\/\/doi.org\/10.1136\/openhrt-2021-001659","journal-title":"Open Heart"},{"key":"4646_CR13","doi-asserted-by":"crossref","unstructured":"Piepoli MF et al (2016) European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37(29):2315\u20132381","DOI":"10.1093\/eurheartj\/ehw106"},{"issue":"11","key":"4646_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK et al (2021) EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol 28(11):1279\u20131289","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"4646_CR15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s11845-021-02885-9","volume":"191","author":"C McCaughey","year":"2022","unstructured":"McCaughey C et al (2022) Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement. Ir J Med Sci 191(6):2569\u20132577","journal-title":"Ir J Med Sci"},{"issue":"10","key":"4646_CR16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.amjcard.2011.01.013","volume":"107","author":"A Kulik","year":"2011","unstructured":"Kulik A et al (2011) Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol 107(10):1409\u20131414","journal-title":"Am J Cardiol"},{"issue":"1","key":"4646_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12944-019-1099-z","volume":"18","author":"PP Toth","year":"2019","unstructured":"Toth PP et al (2019) Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids Health Dis 18(1):175","journal-title":"Lipids Health Dis"},{"issue":"4","key":"4646_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3325\/cmj.2013.54.339","volume":"54","author":"\u017d Reiner","year":"2013","unstructured":"Reiner \u017d, Tedeschi-Reiner E (2013) Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat Med J 54(4):339\u2013345","journal-title":"Croat Med J"},{"issue":"11","key":"4646_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242424","volume":"15","author":"F Sigglekow","year":"2020","unstructured":"Sigglekow F, Horsburgh S, Parkin L (2020) Statin adherence is lower in primary than secondary prevention: a national follow-up study of new users. PLoS One 15(11):e0242424","journal-title":"PLoS One"},{"issue":"8","key":"4646_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","volume":"26","author":"K Kotseva","year":"2019","unstructured":"Kotseva K et al (2019) Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 26(8):824\u2013835","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"4646_CR21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495\u20131504","journal-title":"N Engl J Med"},{"issue":"14","key":"4646_CR22","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352(14):1425\u20131435","journal-title":"N Engl J Med"},{"issue":"21","key":"4646_CR23","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM et al (2008) Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 359(21):2195\u20132207","journal-title":"N Engl J Med"},{"issue":"19","key":"4646_CR24","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR et al (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294(19):2437\u20132445","journal-title":"JAMA"},{"issue":"13","key":"4646_CR25","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG et al (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285(13):1711\u20131718","journal-title":"JAMA"},{"issue":"11","key":"4646_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11883-016-0619-9","volume":"18","author":"KM Goldstein","year":"2016","unstructured":"Goldstein KM et al (2016) Statin Adherence: Does Gender Matter? Curr Atheroscler Rep 18(11):63","journal-title":"Curr Atheroscler Rep"},{"issue":"16","key":"4646_CR27","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.jacc.2018.02.032","volume":"71","author":"SAE Peters","year":"2018","unstructured":"Peters SAE et al (2018) Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States. J Am Coll Cardiol 71(16):1729\u20131737","journal-title":"J Am Coll Cardiol"},{"key":"4646_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.101019","volume":"23","author":"EJB Llanes","year":"2025","unstructured":"Llanes EJB et al (2025) Addressing adherence challenges in long-term statin treatment among Asian populations: current gaps and proposed solutions. Am J Prev Cardiol 23:101019","journal-title":"Am J Prev Cardiol"},{"issue":"8","key":"4646_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.11622\/smedj.2014099","volume":"55","author":"YJ Chee","year":"2014","unstructured":"Chee YJ, Chan HH, Tan NC (2014) Understanding patients\u2019 perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review. Singap Med J 55(8):416\u2013421","journal-title":"Singap Med J"},{"key":"4646_CR30","unstructured":"Executive HS (2024) Chronic Disease Management Programme: Third Report, 2018\u20132023. HSE"},{"issue":"9","key":"4646_CR31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s11886-022-01729-x","volume":"24","author":"A Krishnamurthy","year":"2022","unstructured":"Krishnamurthy A et al (2022) SAMSON and the Nocebo Effect: Management of Statin Intolerance. Curr Cardiol Rep 24(9):1101\u20131108","journal-title":"Curr Cardiol Rep"},{"issue":"12","key":"4646_CR32","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","volume":"78","author":"JP Howard","year":"2021","unstructured":"Howard JP et al (2021) Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol 78(12):1210\u20131222","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"4646_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","volume":"42","author":"J Schubert","year":"2021","unstructured":"Schubert J et al (2021) Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J 42(3):243\u2013252","journal-title":"Eur Heart J"},{"issue":"25","key":"4646_CR34","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP et al (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372(25):2387\u20132397","journal-title":"N Engl J Med"},{"issue":"18","key":"4646_CR35","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS et al (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 376(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"8","key":"4646_CR36","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1177\/2047487320914115","volume":"28","author":"DE Harris","year":"2020","unstructured":"Harris DE et al (2020) Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study. Eur J Prev Cardiol 28(8):854\u2013861","journal-title":"Eur J Prev Cardiol"},{"key":"4646_CR37","first-page":"200229","volume":"20","author":"LG Gebremichael","year":"2024","unstructured":"Gebremichael LG et al (2024) Effectiveness of cardiac rehabilitation programs on medication adherence in patients with cardiovascular disease: A systematic review and meta-analysis. Int J Cardiol Cardiovasc Risk Prev 20:200229","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"1","key":"4646_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F et al (2019) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"key":"4646_CR39","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","volume":"2","author":"A Arrieta","year":"2017","unstructured":"Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K (2017) Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. JAMA Cardiol 2:1369\u20131374. https:\/\/doi.org\/10.1001\/jamacardio.2017.3655","journal-title":"JAMA Cardiol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-026-04646-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:05:41Z","timestamp":1789970741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-026-04646-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":39,"alternative-id":["4646"],"URL":"https:\/\/doi.org\/10.1007\/s11845-026-04646-y","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical review and approval were waived for this study because it is a secondary analysis of an anonymised, previously published dataset collected within the I-ASPIRE study, which adhered to relevant ethical and data protection regulations.","order":1,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed Consent was obtained from all subjects involved in the original I-ASPIRE study. No new participants were recruited for this secondary data analysis.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and\/or the editor(s). MDPI and\/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.","order":3,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}